Cargando…

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies

Detalles Bibliográficos
Autores principales:	Yang, Yang, Du, Lanying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908000/ https://www.ncbi.nlm.nih.gov/pubmed/33637679 http://dx.doi.org/10.1038/s41392-021-00523-5

Ejemplares similares

Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2
por: Fagiani, Francesca, et al.
Publicado: (2020)

The SARS-CoV-2 spike protein: balancing stability and infectivity
por: Berger, Imre, et al.
Publicado: (2020)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
por: Xiaojie, Shi, et al.
Publicado: (2021)

SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines
por: Li, Maochen, et al.
Publicado: (2022)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Adapt or perish: SARS-CoV-2 antibody escape variants defined by deletions in the Spike N-terminal Domain
por: Ribes, Marta, et al.
Publicado: (2021)

SARS-CoV-2 spike protein: flexibility as a new target for fighting infection
por: Pierri, Ciro Leonardo
Publicado: (2020)

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
por: Li, Yang, et al.
Publicado: (2020)

Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies
por: Noorabad Ghahroodi, Faezeh, et al.
Publicado: (2022)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
por: Du, Lanying, et al.
Publicado: (2009)

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
por: Liu, Yang, et al.
Publicado: (2021)

Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection
por: Kalra, Rajkumar Singh, et al.
Publicado: (2021)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein
por: Wang, Junzhi
Publicado: (2020)

Sewer biofilms and SARS-CoV-2
por: Du Toit, Andrea
Publicado: (2023)

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
por: Guan, Xiaoqing, et al.
Publicado: (2023)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

Structural insights into the Omicron spike trimer: tackling the challenges of continuously evolving SARS-CoV-2 variants
por: Ou, Junxian, et al.
Publicado: (2022)

SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes
por: Brewer, R. Camille, et al.
Publicado: (2022)

SARS-CoV-2 rewires host chromatin
por: Du Toit, Andrea
Publicado: (2023)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
por: Lim, Hui Xuan, et al.
Publicado: (2022)

Super(antigen) target for SARS-CoV-2
por: Brown, Matthew, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies
por: Li, Ruofan, et al.
Publicado: (2022)

SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency
por: Li, Maochen, et al.
Publicado: (2021)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

SARS-CoV-2: the many pros of targeting PLpro
por: McClain, Christopher B., et al.
Publicado: (2020)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tdau93fj2nvqdspob9au5h9mhs